Clinical Programs

New Clinical Trials Underway!

The first in a series of new, non-toxic cancer therapies are entering clinical testing! The Sidney Kimmel Cancer Center (SKCC) received permission from the Food and Drug Administration to begin early clinical testing on three promising, new therapies. These are vaccines for recurrent breast cancer (UCLA) and prostate cancer (University of Chicago) as well as an immune implant for recurrent brain cancer (UCLA).

Each of these new therapies could potentially revolutionize cancer treatment and are not available at any other cancer center. These are only part of the pipeline of discoveries under development at SKCC. From this pipeline, therapies against melanoma, ovarian cancer, lung cancer and a variety of solid tumors are projected to enter clinical testing in the next 12-18 months. Collectively, these cancers afflict 1:7 people in their lifetime.